Press Releases

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases. Through this collaboration, Lilly will gain access to Ailux's AI-powered bispecific antibody engineering platform, which integrates advanc

BioDlink (1875.HK) congratulates its partner Lepu Biopharma (2157.HK) on receiving conditional marketing approval from China's National Medical Products Administration (NMPA) for MEIYOUHENG (Becotatug Vedotin injection). This Class 1 innovative antibody-drug conjugate (ADC) targets the epidermal growth factor receptor (EGFR) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Significantly, this is the world's first approved non-photoimmunological EGFR-tar

LakeShore Biopharma Co., Ltd a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into an Agreement and Plan of Merger (the "Merger Agreement") with Oceanpine Skyline Inc. ("Parent") and Oceanpine Merger Sub Inc. ("Merger Sub"), a wholly owned subsidiary of Parent. Pursuant to the Merg

Grit Biotherapeutics Co., Ltd, a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6–9, 2025, in Orlando, Florida, USA. The abstract, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable an

Samsung Biologics today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO). Following approval by its Board of Directors, Samsung Biologics separated its investment and subsidiary management business unit to establish Samsung Epis Holdings. The decision was finalized on November 1, with plans to proceed with registration for the corp

UCB a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and pediatric patients living with thymidine kinase 2 deficiency (TK2d), with an age of symptom onset on or before 12 years.1 It is the first and only approved treatment for these patients living with TK2d. TK2d is an ultra-rare, life-threatening, genetic mitochondrial disease characterized by progressive

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable biosimilars to the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications. The interchangeability (IC) designation is a regulatory designation granted by the FDA, which means STOBOCLO and OSENVELT may now be substituted at the pharmacy for the ref

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has entered into a collaboration with Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease. The partnership agreement will focus on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa's lead cell therapy for the treatment of ovarian

Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is making progress on a dual-continent expansion strategy to meet growing global demand for complex, high-value therapies. Since becoming an independent company in 2023, Simtra has accelerated its growth across North America and Europe, reinforcing its commitment to building advanced capacity and capabilities in both regions. In the United States at i

As patient engagement becomes a cornerstone of clinical, regulatory, and access success, Europe’s life sciences community is preparing to tackle one of its biggest challenges yet: how to measure its true impact. From 2–4 December 2025, senior leaders from across pharma, biotech, and patient advocacy will meet in London for the Measuring Patient Engagement Summit Europe, the first event of its kind dedicated to defining and proving the value of patient engagement. Hosted